Sugi Predict

Sugi Predict / Compounds / SCHEMBL102706

SCHEMBL102706

SCHEMBL102706

CCCCCCCCCCCCCCOCC(CN)OCCCCCCCCCCCCCC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 1/20 0.74
▸ HTT P42858 1/20 0.61
▸ LPAR1 Q92633 7/20 0.56
▸ LPAR3 Q9UBY5 7/20 0.56
▸ LPAR2 Q9HBW0 4/20 0.56
▸ TLR2 O60603 8/20 0.55
▸ USP2 O75604 1/20 0.48
▸ PRKD3 O94806 1/20 0.46
▸ PRKCG P05129 1/20 0.46
▸ PRKCB P05771 1/20 0.46
▸ PRKCA P17252 1/20 0.46
▸ PRKCH P24723 1/20 0.46
▸ PRKCI P41743 1/20 0.46
▸ PRKCE Q02156 1/20 0.46
▸ PRKCQ Q04759 1/20 0.46
▸ PRKCZ Q05513 1/20 0.46
▸ PRKCD Q05655 1/20 0.46
▸ PRKD1 Q15139 1/20 0.46
▸ LPAR6 P43657 3/20 0.45
▸ LPAR4 Q99677 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7564861 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL19839744 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL7559519 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL7558267 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL7560842 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL22589994 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL24470437 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL7560937 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL19839669 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2
SCHEMBL7564999 1.00 DNM1 (0.74) DNM1HTTLPAR1LPAR3LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4333898-A2 PEPTIDE-LIPID CONJUGATES Arcturus Therapeutics, Inc. (US) 2024-03-13 — — EP claimed
WO-2002072068-A2 LIPIDS, LIPID COMPOSITIONS, LIPOSOMES, AND LIPOPLEXES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-09-19 — — WO claimed
EP-4608877-A1 VARIANT RNA-GUIDED CAS12F4 NUCLEASES AND DNA BINDING PROTEINS Inari Agriculture Technology, Inc. (US) 2025-09-03 — — EP disclosed
US-12357705-B2 Negatively charged peg-lipid conjugates ARBUTUS BIOPHARMA CORPORATION (CA) 2025-07-15 — — US disclosed
US-20250114476-A1 POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME GENEVANT SCIENCES GMBH (CH) 2025-04-10 — — US disclosed
EP-4472671-A1 POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME GENEVANT SCIENCES GMBH (CH) 2024-12-11 — — EP disclosed
CN-118900701-A Poly (alkyl oxazoline) -lipid conjugates and compositions containing poly (alkyl oxazoline) lipid particles of (alkyl oxazoline) -lipid conjugates 盖纳万科学有限公司 2024-11-05 — — CN disclosed
CN-118370812-A Modified MRNA vaccine for encoding herpes simplex virus glycoprotein and application thereof 宾夕法尼亚大学理事会 2024-07-23 — — CN disclosed
CN-118251497-A Lipid compositions comprising peptide-lipid conjugates 阿克丘勒斯治疗公司 2024-06-25 — — CN disclosed
CN-118201639-A Peptide-lipid conjugates 阿克丘勒斯治疗公司 2024-06-14 — — CN disclosed
CN-111867634-B Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers 阿尔吉法玛公司 2024-06-11 — — CN disclosed
US-20060083780-A1 Cationic lipids and methods of use PROTIVA BIOTHERAPEUTICS, INC. (CA) 2006-04-20 — — US disclosed
US-20060008910-A1 Lipid encapsulated interfering RNA PROTIVA BIOTHERAPEUTIES, INC. (CA) 2006-01-12 — — US disclosed
WO-2005121348-A1 LIPID ENCAPSULATED INTERFERING RNA PROTIVA BIOTHERAPEUTICS, INC. (CA) 2005-12-22 — — WO disclosed
WO-2005120152-A2 CATIONIC LIPIDS AND METHODS OF USE PROTIVA BIOTHERAPEUTICS, INC. (CA) 2005-12-22 — — WO disclosed
US-20050175682-A1 Polyethyleneglycol-modified lipid compounds and uses thereof PROTIVA BIOTHERAPEUTICS, INC. (CA) 2005-08-11 — — US disclosed
US-20050064595-A1 Lipid encapsulated interfering RNA PROTIVA BIOTHERAPEUTICS, INC. (CA) 2005-03-24 — — US disclosed
WO-2005026372-A1 POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF PROTIVA BIOTHERAPEUTICS, INC. (CA) 2005-03-24 — — WO disclosed
WO-2005007196-A2 LIPID ENCAPSULATED INTERFERING RNA PROTIVA BIOTHERAPEUTICS, INC. (CA) 2005-01-27 — — WO disclosed
WO-2002072068-A2 LIPIDS, LIPID COMPOSITIONS, LIPOSOMES, AND LIPOPLEXES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060008910-A1 Lipid encapsulated interfering RNA NPC1L1, LIPA, SYNCRIP DNM1 917/4885HTT 653/4885LPAR1 28/4885
US-20050064595-A1 Lipid encapsulated interfering RNA ABHD16A, LDLR, RNASE1 DNM1 1717/4885HTT 1073/4885LPAR1 59/4885
US-20050175682-A1 Polyethyleneglycol-modified lipid compounds and uses thereof LIPA, PNLIP, PLTP DNM1 566/4885HTT 3286/4885LPAR1 65/4885
US-12357705-B2 Negatively charged peg-lipid conjugates PHOSPHO1, SGMS1, ABCB4 DNM1 1205/4885HTT 3872/4885LPAR1 69/4885
US-20250114476-A1 POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME PLIN3, PLIN5, MBOAT7 DNM1 501/4885HTT 784/4885LPAR1 42/4885
US-20060083780-A1 Cationic lipids and methods of use LIPA, CETP, PHOSPHO1 DNM1 128/4885HTT 1114/4885LPAR1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.